IVERIC bio, Inc.

NasdaqGS:ISEE Stok Raporu

Piyasa değeri: US$5.5b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

IVERIC bio Yönetim

Yönetim kriter kontrolleri 3/4

IVERIC bio's CEO'su Glenn Sblendorio, Jul2017 tarihinde atandı, in görev süresi 6.17 yıldır. in toplam yıllık tazminatı $ 9.82M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.1% maaş ve 92.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.17% ine doğrudan sahiptir ve bu hisseler $ 9.56M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.5 yıl ve 4.6 yıldır.

Anahtar bilgiler

Glenn Sblendorio

İcra Kurulu Başkanı

US$9.8m

Toplam tazminat

CEO maaş yüzdesi7.1%
CEO görev süresi6yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi5.5yrs
Yönetim Kurulu ortalama görev süresi4.6yrs

Son yönetim güncellemeleri

Recent updates

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Sep 06

IVERIC bio Q2 2022 Earnings Preview

Jul 25

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Jul 05

IVERIC bio: A First Take

Jun 23

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

May 20
We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Feb 01
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Nov 03
IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Sep 28
Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field

Sep 16

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Jul 02
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

Jun 18

IVERIC bio EPS misses by $0.04

May 05

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Mar 12
We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

Nov 27
We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

IVERIC bio EPS misses by $0.05

Nov 02

CEO Tazminat Analizi

Glenn Sblendorio'un ücretlendirmesi IVERIC bio'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2023n/an/a

-US$223m

Dec 31 2022US$10mUS$700k

-US$185m

Sep 30 2022n/an/a

-US$159m

Jun 30 2022n/an/a

-US$141m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$665k

-US$115m

Sep 30 2021n/an/a

-US$107m

Jun 30 2021n/an/a

-US$108m

Mar 31 2021n/an/a

-US$96m

Dec 31 2020US$4mUS$640k

-US$85m

Sep 30 2020n/an/a

-US$77m

Jun 30 2020n/an/a

-US$66m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$2mUS$599k

-US$59m

Sep 30 2019n/an/a

US$63m

Jun 30 2019n/an/a

US$62m

Mar 31 2019n/an/a

US$64m

Dec 31 2018US$1mUS$625k

US$63m

Sep 30 2018n/an/a

-US$51m

Jun 30 2018n/an/a

US$153m

Mar 31 2018n/an/a

US$144m

Dec 31 2017US$3mUS$560k

US$114m

Sep 30 2017n/an/a

US$57m

Jun 30 2017n/an/a

-US$192m

Mar 31 2017n/an/a

-US$200m

Dec 31 2016US$9mUS$373k

-US$193m

Tazminat ve Piyasa: Glenn 'ın toplam tazminatı ($USD 9.82M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 8.11M ).

Tazminat ve Kazançlar: Glenn şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Glenn Sblendorio (67 yo)

6yrs

Görev süresi

US$9,816,150

Tazminat

Mr. Glenn P. Sblendorio, M.B.A., served as the President of IVERIC bio, Inc. (formerly, Ophthotech Corporation) since February 1, 2017 until May 01, 2021 and has been its Chief Executive Officer since July...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Glenn Sblendorio
CEO & Director6yrsUS$9.82m0.17%
$ 9.6m
Pravin Dugel
President & Director2.2yrsUS$4.63m0.15%
$ 8.1m
David Carroll
Senior VP6.3yrsUS$2.68m0.032%
$ 1.8m
Keith Westby
Senior VP & COO6.5yrsUS$2.66m0.029%
$ 1.6m
Christopher Simms
Senior VP & Chief Commercial Officer1.9yrsUS$2.67m0.024%
$ 1.3m
Samir Patel
Co-Founder and Consultant16.5yrsVeri yokVeri yok
Xiao-Ping Dai
Chief Technical Officer2.5yrsVeri yokVeri yok
Kathy Galante
Senior VP of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Todd Anderman
Senior VP5.4yrsVeri yokVeri yok
Amy Sheehan
Senior VP & Chief Human Resources Officer5.5yrsVeri yokVeri yok
Evelyn Harrison
Senior VP & Chief Clinical Operations Officer7.5yrsUS$411.67kVeri yok
Guangping Gao
Chief Strategist of Gene Therapy3.7yrsVeri yokVeri yok

5.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: ISEE 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.5 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Glenn Sblendorio
CEO & Director6.2yrsUS$9.82m0.17%
$ 9.6m
Pravin Dugel
President & Directorless than a yearUS$4.63m0.15%
$ 8.1m
Axel Bolte
Independent Director15.9yrsUS$354.59k0.016%
$ 882.5k
Adrienne Graves
Independent Chairman of the Board4.6yrsUS$398.34k0.016%
$ 882.5k
Mark Blumenkranz
Independent Director3yrsUS$354.59k0.023%
$ 1.3m
Carl Regillo
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Calvin Roberts
Independent Director4.5yrsUS$365.84k0.034%
$ 1.9m
Jane Pritchett Henderson
Independent Director5.5yrsUS$385.84k0.016%
$ 882.5k
Anat Lowenstein
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jeffrey Heier
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Peter Kaiser
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Adnan Tufail
Member of Scientific Advisory Boardno dataVeri yokVeri yok

4.6yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ISEE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).